The incidence of venous thromboembolism (VTE) is steadily increasing and is projected to affect 2 million adults in the United States by 2050. With several treatment options and patient factors to consider, it can be challenging to tailor VTE treatment. This collection focuses on identifying patients at risk, appropriate use of direct oral anticoagulants (DOACs), and strategies for VTE prophylaxis within the hospital setting and for the extended post-discharge period.
Supported by an independent educational grant from
Portola Pharmaceuticals, Inc.
Steering Committee Chair
Consultant Physician, Department of Haematological Medicine, Guys and St. Thomas' NHS Foundation Trust, King's College London, London, United Kingdom
Professor; Chair of the Department of Emergency Medicine, UT Southwestern Medical Center, Dallas, Texas
Professor, University of Washington, Seattle Washington
Clinical Assistant Professor of Pharmacy; Cardiac Critical Care Pharmacist, Presbyterian Healthcare Services, University of New Mexico College of Pharmacy, Albuquerque, New Mexico
Professor of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota
Assistant Professor of Medicine, Harvard Medical School; Director of General Cardiology, Cardiovascular Division, Brigham and Women's Hospital, TIMI Study Group, Boston, Massachusetts